![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC5A12 |
Gene summary for SLC5A12 |
![]() |
Gene information | Species | Human | Gene symbol | SLC5A12 | Gene ID | 159963 |
Gene name | solute carrier family 5 member 12 | |
Gene Alias | SMCT2 | |
Cytomap | 11p14.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q1EHB4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
159963 | SLC5A12 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.85e-04 | 3.29e-01 | 0.0171 |
159963 | SLC5A12 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.56e-07 | 1.84e-01 | 0.0674 |
159963 | SLC5A12 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.38e-30 | 6.55e-01 | 0.3005 |
159963 | SLC5A12 | HCC1_Meng | Human | Liver | HCC | 1.17e-29 | 1.21e-01 | 0.0246 |
159963 | SLC5A12 | HCC1 | Human | Liver | HCC | 3.12e-03 | 2.49e+00 | 0.5336 |
159963 | SLC5A12 | HCC2 | Human | Liver | HCC | 5.93e-12 | 2.43e+00 | 0.5341 |
159963 | SLC5A12 | HCC5 | Human | Liver | HCC | 5.65e-04 | 2.47e-01 | 0.4932 |
159963 | SLC5A12 | S014 | Human | Liver | HCC | 3.54e-04 | 1.40e-01 | 0.2254 |
159963 | SLC5A12 | S016 | Human | Liver | HCC | 1.12e-03 | 1.34e-01 | 0.2243 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC5A12 | SNV | Missense_Mutation | c.12N>T | p.Lys4Asn | p.K4N | Q1EHB4 | protein_coding | tolerated(0.36) | benign(0.25) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC5A12 | SNV | Missense_Mutation | rs868770781 | c.160N>A | p.Gly54Ser | p.G54S | Q1EHB4 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | c.1691A>G | p.Asp564Gly | p.D564G | Q1EHB4 | protein_coding | tolerated(0.17) | benign(0.058) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SLC5A12 | SNV | Missense_Mutation | c.799A>G | p.Lys267Glu | p.K267E | Q1EHB4 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SLC5A12 | SNV | Missense_Mutation | rs781457760 | c.1583N>A | p.Arg528His | p.R528H | Q1EHB4 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | rs750972474 | c.751N>A | p.Gly251Arg | p.G251R | Q1EHB4 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | rs145373937 | c.370N>T | p.Arg124Cys | p.R124C | Q1EHB4 | protein_coding | deleterious(0.02) | possibly_damaging(0.723) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
SLC5A12 | SNV | Missense_Mutation | rs199554975 | c.1285G>A | p.Val429Met | p.V429M | Q1EHB4 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | rs367554725 | c.1388C>T | p.Ala463Val | p.A463V | Q1EHB4 | protein_coding | deleterious(0.04) | benign(0.006) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
SLC5A12 | SNV | Missense_Mutation | novel | c.681N>A | p.Asp227Glu | p.D227E | Q1EHB4 | protein_coding | deleterious(0) | possibly_damaging(0.718) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |